Differential KEAP1/NRF2 mediated signaling widens the therapeutic window of redox-targeting drugs in SCLC therapy
Jana Samarin,Hana Nuskova,Piotr Fabrowski,Mona Malz,Eberhard Amtmann,Minerva Jazmin Taeubert,Daniel Pastor-Flores,Daniel Kazdal,Roman Kurilov,Franziska Deis,Hanne Pink,Johanna Hummel-Eisenbeiss,Nicole deVries,Kamini Kaushal,Tobias Dick,Gerhard Hamilton,Martina Muckenthaler,Moritz Mall,Bryce Lim,Taishi Kanamaru,Glynis Klinke,Martin Sos,Julia Frede,Aubry Miller,Hamed Alborzinia,Nikolas Gunkel
DOI: https://doi.org/10.1101/2024.11.06.621846
2024-11-07
Abstract:Small cell lung cancer (SCLC) patients frequently experience a remarkable response to first-line therapy. Follow up maintenance treatments aim to control residual tumor cells, but generally fail due to cross-resistance, inefficient targeting of tumor vulnerabilities, or dose-limiting toxicity, resulting in relapse and disease progression. Here, we show that SCLC cells, similar to their cells of origin, pulmonary neuroendocrine cells (PNECs), exhibit low activity in pathways protecting against reactive oxygen species (ROS). When exposed to a novel thioredoxin reductase 1 (TXNRD1) inhibitor, these cells quickly exhaust their ROS-scavenging capacity, regardless of their molecular subtype or resistance to first-line therapy. Importantly, unlike non-cancerous cells, SCLC cells cannot adapt to drug-induced ROS stress due to the suppression of ROS defense mechanisms by multiple layers of epigenetic and transcriptional regulation. By exploiting this difference in oxidative stress management, we safely increased the therapeutic dose of TXNRD1 inhibitors in vivo by pharmacological activation of the NRF2 stress response pathway. This resulted in improved tumor control without added toxicity to healthy tissues. These findings underscore the therapeutic potential of TXNRD1 inhibitors for maintenance therapy in SCLC.
Cancer Biology